- Home
- RPD vs SGP Comparison
RPD vs SGP Comparison
Compare RPD & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPD | SGP |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.5M | 932.9M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | RPD | SGP |
|---|---|---|
| Price | $5.85 | $22.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 22 | 5 |
| Target Price | $15.05 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 2.0M | 67.1K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $685,083,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.54 | N/A |
| P/E Ratio | $16.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.97 | $20.15 |
| 52 Week High | $27.10 | $30.56 |
Technical Indicators
Market Signals| Indicator | RPD | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 42.51 |
| Support Level | $5.10 | $20.60 |
| Resistance Level | $6.09 | $26.55 |
| Average True Range (ATR) | 0.40 | 1.47 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 51.74 | 44.75 |
Price Performance
Historical ComparisonAbout RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.